Novartis to sell blood transfusion Dx arm for $1.7B; Scottish researchers launch lung cancer blood test study;

> Novartis ($NVS) plans to sell its blood transfusion diagnostics arm to Spain's Grifols for $1.7 billion. Story

> California's Genmark Diagnostics ($GNMK) generated $4.6 million in revenue during its 2013 third quarter and more than $10.8 million in net losses, declines shaped, in part, by the lack of purchases by a major customer. Item

> The Infectious Diseases Society of America is calling for the development of more diagnostic tests that are easy to use, can identify a bug causing an infection and generate quicker results compared with current tests. Item

> IntelligentMDx in Massachusetts won FDA clearance for a new C. difficile test designed for use on Abbott's ($ABT) fully automated m2000 system. The company also completed moving its operations to Waltham. Item

> Scottish researchers are launching a massive study of a blood test designed to detect lung cancer before symptoms start showing. Story

Suggested Articles

In an SEC filing, Baxter International disclosed that it may have overstated its income over multiple years, inflating it by about $276 million.

The FDA has given Grail a green light to conduct the interventional study, and it has begun enrolling participants through the company’s R&D partners.

Coronavirus may not require a front-line battle yet in certain places, but it’s still taxing public health officials preparing for a potential crisis.